S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021.
作者信息
Dippel Edgar, Assaf Chalid, Becker Jürgen C, von Bergwelt-Baildon Michael, Bernreiter Sophie, Cozzio Antonio, Eich Hans T, Elsayad Khaled, Follmann Markus, Grabbe Stephan, Hillen Uwe, Klapper Wolfram, Klemke Claus-Detlev, Loquai Carmen, Meiss Frank, Mitteldorf Christina, Wehkamp Ulrike, Nashan Dorothee, Nicolay Jan P, Oschlies Ilske, Schlaak Max, Stranzenbach René, Moritz Rose, Stoll Christoph, Vag Tibor, Weichenthal Michael, Wobser Marion, Stadler Rudolf
机构信息
Department of Dermatology, Hospital Ludwigshafen, Germany.
Department of Dermatology and Venereology, Helios Hospital Krefeld, Germany.
出版信息
J Dtsch Dermatol Ges. 2022 Apr;20(4):537-554. doi: 10.1111/ddg.14706.
Abstract
摘要
相似文献
1
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021.S2k指南 - 皮肤淋巴瘤（ICD10 C82 - C86）：2021年更新
J Dtsch Dermatol Ges. 2022 Apr;20(4):537-554. doi: 10.1111/ddg.14706.
2
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).S2k指南 - 皮肤淋巴瘤2016年更新 - 第2部分：治疗与随访（ICD10 C82 - C86）
J Dtsch Dermatol Ges. 2018 Jan;16(1):112-122. doi: 10.1111/ddg.13401. Epub 2017 Dec 27.
3
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86).S2k指南 - 皮肤淋巴瘤2016年更新 - 第1部分：分类与诊断（ICD10 C82 - C86）
J Dtsch Dermatol Ges. 2017 Dec;15(12):1266-1273. doi: 10.1111/ddg.13372. Epub 2017 Nov 28.
4
[Management of cutaneous T-cell lymphomas: Recommendations of the French Cutaneous Lymphoma Group].[皮肤T细胞淋巴瘤的管理：法国皮肤淋巴瘤小组的建议]
Ann Dermatol Venereol. 2010 Oct;137(10):611-21. doi: 10.1016/j.annder.2010.06.021.
5
Bridging the specialty gap: Update on primary cutaneous lymphomas.弥合专业差距：原发性皮肤淋巴瘤的最新进展
J Am Acad Dermatol. 2024 Feb;90(2):257-260. doi: 10.1016/j.jaad.2023.10.007. Epub 2023 Dec 1.
6
7
Evaluation of cutaneous lymphomas.皮肤淋巴瘤的评估。
Compr Ther. 1996 Mar;22(3):169-74.
8
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.原发性皮肤淋巴瘤：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2013 Oct;24 Suppl 6:vi149-54. doi: 10.1093/annonc/mdt242. Epub 2013 Jul 17.
9
Cutaneous lymphomas-An update 2019.皮肤淋巴瘤-2019 更新。
Hematol Oncol. 2019 Jun;37 Suppl 1:43-47. doi: 10.1002/hon.2584.
10
Management of primary cutaneous lymphomas during the COVID-19 pandemic.COVID-19 大流行期间原发性皮肤淋巴瘤的治疗管理。
Clin Dermatol. 2021 Jan-Feb;39(1):64-75. doi: 10.1016/j.clindermatol.2020.12.014. Epub 2021 Jan 9.
引用本文的文献
1
Modern approaches to radiotherapy in primary cutaneous lymphomas: insights and recommendations from the DEGRO dermato-oncology working group.原发性皮肤淋巴瘤放射治疗的现代方法：DEGRO皮肤肿瘤学工作组的见解与建议
Strahlenther Onkol. 2025 Sep 9. doi: 10.1007/s00066-025-02453-5.
2
Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma.评估莫加莫拉单抗治疗原发性皮肤T细胞淋巴瘤的疗效。
Immunotherapy. 2025 Jun;17(8):551-559. doi: 10.1080/1750743X.2025.2520153. Epub 2025 Jun 24.
3
Alopecia Mimicking Lichen Planopilaris in a Patient with Mycosis Fungoides.蕈样肉芽肿患者中类似扁平苔藓样毛发扁平苔藓的脱发
Skin Appendage Disord. 2025 Jun;11(3):296-301. doi: 10.1159/000543256. Epub 2024 Dec 28.
4
Scalp Involvement in Primary Cutaneous Lymphomas-An Update on Clinical Presentation, Diagnostics, and Management.原发性皮肤淋巴瘤的头皮受累——临床表现、诊断及管理的最新进展
Cancers (Basel). 2025 May 16;17(10):1678. doi: 10.3390/cancers17101678.
5
Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany.德国莫加莫拉单抗治疗患者的治疗与监测实用建议。
J Dtsch Dermatol Ges. 2025 Mar;23(3):341-354. doi: 10.1111/ddg.15639. Epub 2024 Dec 26.
6
Nanopore Sequencing for T-Cell Receptor Rearrangement Analysis in Cutaneous T-Cell Lymphoma.用于皮肤T细胞淋巴瘤中T细胞受体重排分析的纳米孔测序
Cancers (Basel). 2024 Nov 1;16(21):3700. doi: 10.3390/cancers16213700.
7
Health-related quality of life in primary cutaneous B-cell lymphoma following local radiotherapy.局部放疗后原发性皮肤B细胞淋巴瘤患者的健康相关生活质量
JAAD Int. 2024 Jul 30;17:53-54. doi: 10.1016/j.jdin.2024.07.002. eCollection 2024 Dec.
8
Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases.莫格利珠单抗联合低分割小剂量全身电子束照射（2×4Gy）治疗皮肤 T 细胞淋巴瘤：初步研究，两例报告。
Curr Oncol. 2024 Sep 13;31(9):5412-5421. doi: 10.3390/curroncol31090400.
9
Proceedings from the First Onco Summit: LATAM Chapter, 19-20 May 2023, Rio de Janeiro, Brazil.第一届肿瘤学峰会会议记录：拉丁美洲分会，2023年5月19日至20日，巴西里约热内卢
Cancers (Basel). 2024 Sep 3;16(17):3063. doi: 10.3390/cancers16173063.
10
Adrenal Insufficiency after Long-term use of Topical Glucocorticoids in Patients with Advanced Cutaneous T-cell Lymphomas: A Case Series.晚期皮肤T细胞淋巴瘤患者长期使用外用糖皮质激素后发生肾上腺皮质功能不全：病例系列
Acta Derm Venereol. 2024 Apr 2;104:adv19672. doi: 10.2340/actadv.v104.19672.
本文引用的文献
1
Quality of life in patients with mycosis fungoides and Sézary syndrome undergoing low-dose total skin electron beam therapy with or without maintenance therapy.蕈样肉芽肿和塞扎里综合征患者接受低剂量全身电子束治疗联合或不联合维持治疗的生活质量。
J Am Acad Dermatol. 2022 Apr;86(4):889-891. doi: 10.1016/j.jaad.2021.03.025. Epub 2021 Mar 17.
2
Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: A neglected topic.蕈样肉芽肿或塞扎里综合征患者的维持治疗：一个被忽视的话题。
Eur J Cancer. 2021 Jan;142:38-47. doi: 10.1016/j.ejca.2020.10.007. Epub 2020 Nov 17.
3
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.抗 CCR4 单克隆抗体 Mogamulizumab 与 Vorinostat 治疗皮肤 T 细胞淋巴瘤患者的生活质量影响。
Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):97-105. doi: 10.1016/j.clml.2020.09.003. Epub 2020 Sep 18.
4
Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma.当前措施并不充分：一项基于访谈的皮肤T细胞淋巴瘤生活质量定性评估
Br J Dermatol. 2021 Feb;184(2):310-318. doi: 10.1111/bjd.19298. Epub 2020 Aug 2.
5
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.复发/难治性皮肤 T 细胞淋巴瘤患者的患者报告生活质量：来自随机 III 期 ALCANZA 研究的结果。
Eur J Cancer. 2020 Jul;133:120-130. doi: 10.1016/j.ejca.2020.04.010. Epub 2020 Jun 2.
6
Combined total skin radiotherapy and immune checkpoint inhibitors: A promising potential treatment for mycosis fungoides and Sezary syndrome.联合全身皮肤放射治疗和免疫检查点抑制剂：蕈样肉芽肿和塞扎里综合征有前途的潜在治疗方法。
J Dtsch Dermatol Ges. 2020 Mar;18(3):193-197. doi: 10.1111/ddg.14044. Epub 2020 Feb 20.
7
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.波拉珠单抗维地布用于复发/难治弥漫性大 B 细胞淋巴瘤。
J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6.
8
Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome.低剂量全身电子束治疗：蕈样肉芽肿或塞扎里综合征患者维持和辅助治疗的生活质量改善和临床影响。
Strahlenther Onkol. 2020 Jan;196(1):77-84. doi: 10.1007/s00066-019-01517-7. Epub 2019 Oct 7.
9
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.IPH4102，一种首创的抗 KIR3DL2 单克隆抗体，用于治疗复发或难治性皮肤 T 细胞淋巴瘤患者：一项国际性、首创的、开放标签、1 期临床试验。
Lancet Oncol. 2019 Aug;20(8):1160-1170. doi: 10.1016/S1470-2045(19)30320-1. Epub 2019 Jun 25.
10
Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.来自前瞻性皮肤淋巴瘤国际预后指数（PROCLIPI）研究的蕈样肉芽肿/赛塞里综合征中与生活质量显著较差相关的特征。
Br J Dermatol. 2020 Mar;182(3):770-779. doi: 10.1111/bjd.18089. Epub 2019 Jul 28.
Zotero 插件